on like for few This we next bring to process. that for focus a steps as dynamics the themes market our through a regulatory Rita. help very to therapy. VAZALORE today you, exciting give Thank a the time is us the reasons will key and of significant I'd aspirin VAZALORE, believe launching our us in of I confidence that illustrate amount enthusiasm behind the novel
First, let me market instrumental of product Data be compelling target informing aspirin will clinical reiterate healthcare our of our our in innovative believe remind briefly professional VAZALORE. that opportunity we the data. you and
are targeting market. secondary prevention sizable We encompasses the in critical We a groups. VAZALORE which see population this for role two
don't level for event a having but heart have First, diabetics people their such a who have a And an disease higher at or by event. vascular necessarily second, condition virtue vascular experienced risk who have attack, heart stroke, undergone who a as of procedure. are
patient patients market of billion meaningful a VAZALORE even Taken small By potential opportunity. importantly, together, generate impact $XX to these share for segments market represent over capturing and huge million market, that a a lives. many revenue, XX has
lipid now faster, filled VAZALORE the me compared supporting liquid overview duodenum. with to clinical a aspirin more absorbed capsules standard-of-care. Let aspirin, VAZALORE’s stomach enteric-coated complex gets formulation and the with the that data what and turn an in reliable absorption bypasses aspirin are of Accordingly, and so VAZALORE category. the provide the aspirin makes current inhibition unique better in rapidly platelet
advantage toxicity comes efficacy this improved compared the Importantly, added with aspirin. of GI regular less with
American as and for XXXX PK and study Top Bhatt PD and platelet the was achieved faster, from efficacy Women's Brigham aspirin, Harvard as and to as of X enteric-coated the VAZALORE VAZALORE X showed Dr. X robust up better Principal College therapeutic greater absorption compared of Investigator. recognized one response. times of comparison a with Deepak of the and aspirin Journal Picks study, was enteric-coated Cardiology to regular that Headlines the aspirin published and in times Our of editor-in-chief’s times
of American aspirin endoscopy. our GI via the and in in of damage Another study upper Gastroenterology healthy published Journal compared VAZALORE subjects regular
an NNT, treat for that save XX% a the needed measure By risk treat or performance. economic patients or X Our to X X an to ulcers them. of with erosions or is and NNT, blinded the with XX% need means risk of third-party of treat of only VAZALORE of an studies NNT review endoscopic you drug’s clinical X. number to one An X, definition, of number NNT ulcers that X lower to needed lower demonstrated revealed of accepted
let leaders professionals, engage groups, strategies Now, turn trade. our commercial to important to our and retail X healthcare on me the commercialization. to Key in consumers approach with
to awareness build and brand conferences among major and and educate to continue awareness in important practitioners end, key raise actively these that To conferences we’ve build participate several top prestigious constituents. among to familiarity We in leaders. thought participated
EuroPCR, new We heard could benefit of May, the And the science VAZALORE soon therapy thrilled were risk millions for formulation coming as high we that mentioned aspirin in gathering was a patients. leaders In specifically Europe, patients. participated anti-platelet benefit reliable innovative an we need reiterate latest improved communicated. with risk profile lifelong in are cardiologists for and the interventional advances where thought largest cardiovascular of when
the to convinced aspirin of the U.S. to launch We we're our but safety globally. our on enhanced remain in clinicians laser-focused efficacy consider resonates efforts also plan And among we that and VAZALORE global opportunities novel outcomes proposition value ISPOR around two at patients the the available note, that VAZALORE's health to presented would for the and Also on world. VAZALORE economics conference abstracts make of Conference, research. we leading reliable
safety of bleeding alternative entitled large improved of use aspirin is enteric-coated is, to specifically the And generation, need added during switching of GI with and acute first hospital contribute next safer acute aspirin aspirin impact with hospitalization attacks aspirin for costs The The patients strokes. with second events. heart underscore or of formulation effective a option. the vascular for complications the an budget limitations GI associated upper can treatment
can significant treatment hospital and cost the the We on superior protocols the of based formulations bleeding. use on of savings instead VAZALORE risk demonstrated patients safety into GI high acute currently translate of for of reduced these that budgets risk available
in meetings. We on VAZALORE to in also present chronic economic are can setting contribute benefits our that plan findings our upcoming and the treatment continuing work the
the and such both to influential world, them the present the inform attended Forums about and important VAZALORE these These that for part will purchase its regimen be of are clinical benefits, of is well consumer From an daily the perspective, to secondary and unique practitioners VAZALORE thus prevention. us patients as a ensure by in physician. require are because most and economic, opportunities understood. therapy between the consumers’ lifetime decision to over-the-counter as aspirin product, this their
price for product physician, will patients pay in a seek Further, when by it. OTC to that a willing premium recommended are that out an and the store our is research product shows
meetings aspirin a long enthusiasm continue planning a in dialogues have the indicated overdue and expressed They've We strong to with who investment innovation VAZALORE. key interest and retailers in category. productive for their have
to Finally, PLx as as to Texas relocated the have corporate we our from from launch Jersey, prepare VAZALORE. of headquarters New continue for to development we transition we commercialization,
thoughts a to and lives. market many share to me let VAZALORE bringing about we on conclusion, patients’ the excited couple of so so why In opportunity are impact
an physicians has offer First, in vascular to we and mechanism strong innovation believe through VAZALORE critical address secure of an unmet unique enabled over-the-counter action product for Its treatment patent can life us XXXX. very of need, disease. an a
utilizes our provide novel to Second, which efficacy enables it and drug safety. delivery platform, PLx improved VAZALORE GI better
With these can benefits, to believe VAZALORE. we key the we current transform standard-of-care
with finally, communities neurology continuing thought to and our aspirin cardiology disrupt for progress key potential look our confirmed We And and leaders our in to launch. forward its the conversations the enthusiasm VAZALORE landscape. have toward
to the like Operator, please I'd for open that, with go instructions. questions. the call ahead With
